Overview

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone
Xhance